These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38105681)

  • 1. Cellular and molecular alterations in a human hepatocellular in vitro model of nonalcoholic fatty liver disease development and stratification.
    Willett RA; Tryndyak VP; Beland FA; Pogribny IP
    J Environ Sci Health C Toxicol Carcinog; 2024; 42(1):74-92. PubMed ID: 38105681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of differentially methylated region (DMR) networks associated with progression of nonalcoholic fatty liver disease.
    Hotta K; Kitamoto A; Kitamoto T; Ogawa Y; Honda Y; Kessoku T; Yoneda M; Imajo K; Tomeno W; Saito S; Nakajima A
    Sci Rep; 2018 Sep; 8(1):13567. PubMed ID: 30206277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for aberrantly methylated and differentially expressed genes in nonalcoholic fatty liver disease of hepatocellular carcinoma patients with cirrhosis.
    Zhang G; Hou Y
    World J Surg Oncol; 2022 Nov; 20(1):364. PubMed ID: 36397165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of autophagy impairs free fatty acid-induced excessive lipid accumulation in hepatocellular carcinoma and hepatic cells.
    Chen X; Liu H; Chen K; Guo Y; Mo T; Gao T
    J Biosci; 2022; 47():. PubMed ID: 36210729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic transcriptome signatures in mice and humans with nonalcoholic fatty liver disease.
    Ding Y; Dai X; Bao M; Xing Y; Liu J; Zhao S; Liu E; Yuan Z; Bai L
    Animal Model Exp Med; 2023 Aug; 6(4):317-328. PubMed ID: 37565549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two differentially methylated region networks in nonalcoholic fatty liver disease, viral hepatitis, and hepatocellular carcinoma.
    Kurokawa S; Yoneda M; Ogawa Y; Honda Y; Kessoku T; Imajo K; Saito S; Nakajima A; Hotta K
    BMC Gastroenterol; 2022 Jun; 22(1):278. PubMed ID: 35655171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative transcriptomic analysis of NAFLD animal model reveals dysregulated genes and pathways in metabolism.
    Yang W; He Y; Liu S; Gan L; Zhang Z; Wang J; Liang J; Dong Y; Wang Q; Hou Z; Yang L
    Gene; 2016 Dec; 595(1):99-108. PubMed ID: 27697615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis.
    Chatterjee A; Basu A; Das K; Singh P; Mondal D; Bhattacharya B; Roychoudhury S; Majumder PP; Chowdhury A; Basu P
    Ann Hepatol; 2020; 19(5):472-481. PubMed ID: 32682086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research progress of omics biomarkers for nonalcoholic fatty liver disease].
    Wang L; Liu XE; Zhuang H
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):604-608. PubMed ID: 34225440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function.
    Zhang J; Zhang W; Yang L; Zhao W; Liu Z; Wang E; Wang J
    Phytomedicine; 2023 Jan; 109():154589. PubMed ID: 36610145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating Nonalcoholic Fatty Liver Disease in a Liver-on-a-Chip Microfluidic Device.
    Gori M; Simonelli MC; Giannitelli SM; Businaro L; Trombetta M; Rainer A
    PLoS One; 2016; 11(7):e0159729. PubMed ID: 27438262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests.
    Di Ciaula A; Calamita G; Shanmugam H; Khalil M; Bonfrate L; Wang DQ; Baffy G; Portincasa P
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
    Enooku K; Tsutsumi T; Kondo M; Fujiwara N; Sasako T; Shibahara J; Kado A; Okushin K; Fujinaga H; Nakagomi R; Minami T; Sato M; Uchino K; Nakagawa H; Kondo Y; Asaoka Y; Tateishi R; Ueki K; Ikeda H; Yoshida H; Moriya K; Yotsuyanagi H; Kadowaki T; Koike K
    J Gastroenterol; 2020 Feb; 55(2):227-243. PubMed ID: 31602526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Water Extract of Dolichos lablab Attenuates Hepatic Lipid Accumulation in a Cellular Nonalcoholic Fatty Liver Disease Model.
    Im AR; Kim YH; Lee HW; Song KH
    J Med Food; 2016 May; 19(5):495-503. PubMed ID: 27152979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma.
    Alqahtani SA; Chan WK; Yu ML
    Clin Liver Dis; 2023 May; 27(2):211-223. PubMed ID: 37024203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.